Effect of polymorphic CYP2C19 genotype on the pharmacokinetics and pharmacodynamics of clopidogrel in healthy subjects

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN39669611

Enrollment

Registered

2007-09-17

Start date

2007-03-01

Completion date

Unknown

Last updated

2019-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular diseases Circulatory System Cardiovascular diseases

Interventions

After a loading dose of clopidogrel (300 mg

oral), patients will take a standard dose of clopidogrel 75 mg once a day for 6 days. The following will be carried out: 1. Assessment of PK of clopidogrel and its met

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1. Healthy male subjects aged between 19 to 55 2. Wish to participate in the study 3. Informed consent for the trial

Exclusion criteria

Exclusion criteria: 1. A history of or currently active clinically significant cardiac (including clinically significant abnormalities on Electrocardiogram [ECG] according to Principal Investigator [PI]), pulmonary, gastrointestinal, hepatic, renal, pancreatic, or neurological disease 2. Heavy smoker and alcohol consumer 3. Use of anticoagulants or medication within the last 1 month

Design outcomes

Primary

Measure	Time frame
Genetic association with biological effect of clopidogrel.	—

Secondary

Measure	Time frame
PK/PD relationship.	—

Countries

Korea, South

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026